71 indexable Oncology companies headquartered in Florida, United States, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $1B across 37 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Enveric
Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders |
$26.4M | — | Public | Post IPO Apr 2026 | 25 | 1994 | ↑ Active |
| 2 |
TuHURA Biosciences
Developer of immunotherapies for the treatment of cancer |
$37.8M | — | Public | Unattributed Oct 2025 | — | 1996 | ↑ Active |
| 3 |
DermaSensor
Developer of an AI-powered skin cancer detection device |
$35.8M | — | Series B | Series B Oct 2025 | 24 | 2009 | ↑ Active |
| 4 |
Black Light Surgical
Developer of a device for imaging diagnostics of cancer |
$12.9M | — | Series A | Series A Jun 2025 | 1 | 2016 | ↑ Active |
| 5 |
Mel-Mont Medical
Developer of molecular screening devices for the early detection of infectious diseases |
$3M | — | Series A | Series A Dec 2025 | 4 | 2014 | ↑ Active |
| 6 |
Myosin Therapeutics
Developer of therapeutics for CNS-based disorders |
$3M | — | Seed | Grant (prize money) Aug 2025 | 8 | 2020 | ↑ Active |
| 7 |
Syncromune
Developer of therapeutic vaccines for the treatment of cancer |
$14.2M | — | Series A | Series A Dec 2024 | 13 | 2020 | ↑ Active |
| 8 |
Modulation Therapeutics
Developing innovative therapies targeting cancer and liver disease |
$5.2M | — | Series A | Grant (prize money) Mar 2025 | — | 2011 | ↑ Active |
| 9 |
Oragenics
Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health |
$87.3M | — | Public | Post IPO Aug 2023 | 5 | 1996 | — |
| 10 |
NeoGenomics
Provider of cancer genetic diagnostic services |
$445.5M | — | Public | Post IPO Jan 2021 | 2,100 | 2002 | — |
| 11 |
NOK Therapeutics
Developer of autologous natural killer (NK) cell therapies for cancer |
$1.9M | — | Seed | Seed Oct 2024 | — | 2024 | ↑ Active |
| 12 |
Mirror Biologics
Developer of next-generation immunotherapy products |
$30M | — | Series A | Series A Oct 2022 | 20 | 2018 | — |
| 13 |
Blink Bio
Develops technologies for targeted delivery of therapeutics |
$59.3M | — | Series D | Conventional Debt Jul 2019 | 8 | 2009 | — |
| 14 |
Stem Synergy
Biotechnology company discovering novel cancer therapeutics targeting fundamental mechanisms |
$14M | — | Funding Raised | Grant (prize money) Apr 2022 | 8 | 2007 | — |
| 15 |
X-VAX Technology
Developer of virus-based vaccines for treating herpes |
$56.5M | — | Deadpooled | Series A Jul 2019 | 12 | 2017 | — |
| 16 |
BMRT
Provider of devices for diagnosis of cancer |
$3.1M | — | Series A | Series A Nov 2023 | — | 2023 | — |
| 17 |
Xcovery
Kinase inhibitors to treat non-small cell lung cancer |
$37.5M | — | Series B | Series B May 2015 | 18 | 2006 | — |
| 18 |
Vigilant Biosciences
Point of care and lab solutions for detection of cancer |
$29.8M | — | Series B | Series B May 2018 | 26 | 2011 | — |
| 19 |
Intezyne
Clinical-stage company developing drugs for the treatment of various tumor diseases |
$19.3M | — | Series A | Series A Oct 2017 | 4 | 2004 | — |
| 20 |
AIM ImmunoTech
Developer of drugs for various immune-related diseases and cancer |
$10.1M | — | Public | Post IPO Aug 2019 | 185 | 1966 | — |
| 21 |
Imaging Diagnostic Systems
Innovating non-invasive laser breast imaging technology for early detection |
$25M | — | Series A | Series A Aug 2000 | 4 | 1994 | — |
| 22 |
VeriTeQ
Medical device hardware and service provider with RFID implantable technology |
$13.9M | — | Public | Post IPO Mar 2015 | 11 | 1995 | — |
| 23 |
Sensus Healthcare
Medical device company specializing in non-invasive skin cancer and keloid treatments |
$12.2M | — | Public | Series A Jan 2016 | 42 | 2010 | — |
| 24 |
QSAM Biosciences
Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation |
$4.5M | — | Public | Post IPO Jan 2021 | 4 | 2004 | — |
| 25 |
BioCurity
Developer of nanoparticle-based drugs for cancer treatment |
$556K | — | Seed | Seed Jun 2023 | 1 | 2010 | — |
| 26 |
Sun BioPharma
Therapeutics for pancreatic cancer |
$4M | — | Public | Post IPO Sep 2019 | 4 | 2011 | — |
| 27 |
Vector Vitale
Developer of bio-molecule-based therapeutics for the treatment of oncology and other degenerative diseases |
$1.1M | — | Seed | Seed May 2022 | 4 | 2014 | — |
| 28 |
Medite
Developer of products for histology and cytology |
$2.6M | — | Public | Post IPO Oct 2018 | 71 | 1978 | — |
| 29 |
MDNA Life Sciences
Provider of genomic and molecular diagnostics based on the mitochondrial genome |
$1.2M | — | Acquired | Seed Jan 2019 | 8 | 2001 | — |
| 30 |
NovelStem
Developer of stem cell-based diagnostics to predict patients resistance to cancer chemotherapies |
$700K | — | Late Stage | PE Apr 2016 | 15 | 1993 | — |
| 31 |
Cvergenx
Genomic informatics company personalizing radiation therapy with precision genomic radiation therapy platform |
$615.6K | — | Seed | Seed Dec 2015 | 3 | 2009 | — |
| 32 |
Aurora BioPharma
CAR T cell based immunotherapies for solid cancers. |
$440K | — | Seed | Seed Dec 2016 | — | 2015 | — |
| 33 |
Diverse Biotech
Developer of therapeutics for treating cancer |
$337.9K | — | Seed | Seed Sep 2019 | 6 | 2017 | — |
| 34 |
Venn Therapeutics
Developer of immunotherapies for treating cancer |
$225K | — | Funding Raised | Grant (prize money) Sep 2019 | 6 | 2015 | — |
| 35 |
Epigenetix
Pioneering epigenetic therapies for cancer, targeting novel drug discovery and development |
$167.2K | — | Series A | Grant (prize money) Sep 2016 | — | 2011 | — |
| 36 |
PanAm HIFU
Foreign language education and research institute at a Chinese university |
$150K | — | Deadpooled | Conventional Debt Jul 2014 | — | 2006 | — |
| 37 |
ProCare Diagnostics
Developer of next-generation diagnostic tests for prostate cancer |
$58K | — | Seed | Seed Oct 2016 | — | 2015 | — |
| 38 |
Empyrean Medical Systems
Developer of AI enabled radiotherapy platform to treat cancer |
— | — | Seed | Seed Jan 2026 | 18 | 2019 | ↑ Active |
| 39 |
AAVet Therapeutics
Viral-based vaccines for the treatment and prevention of cancer |
— | — | Deadpooled | — | — | 2016 | — |
| 40 |
Advanced Innovative Partners
Radiopharmaceutical company advancing healthcare through innovative diagnostic and therapeutic solutions |
— | — | Unfunded | — | — | 2016 | — |
| 41 |
Avatar DSS
Precision treatment support for cancer patients |
— | — | Funding Raised | — | — | 2015 | — |
| 42 |
Biotest Pharmaceuticals
Manufactures bio therapeutics in immunology and liver |
— | — | Acquired | — | 1,406 | 2007 | — |
| 43 |
Blue Physics
Developer of radiation therapy for the treatment of cancer |
— | — | Unfunded | — | — | 2015 | — |
| 44 |
BreakBio
Developer of personalized cancer treatment through advanced AI technology |
— | — | Unfunded | — | — | 2019 | — |
| 45 |
cell vault
Cell Vault offers a t-cell bank that gives healthy individuals an opportunity to jumpstart their fight against cancer. |
— | — | Deadpooled | — | 3 | 2019 | — |
| 46 |
Cytorex
Biotechnology company developing ionic therapeutic technology for brain tumors |
— | — | Unfunded | — | — | 2009 | — |
| 47 |
CZ Biomed
Injection molding accessories and equipment supplier, offering comprehensive solutions |
— | — | Deadpooled | — | — | 2009 | — |
| 48 |
DELiver Therapeutics
Developer of next-generation therapeutics for cancer and aging disorders |
— | — | Funding Raised | — | 6 | 2021 | — |
| 49 |
dermasensor
DermaSensor Inc. is a health technology company designing tools to better equip primary care providers for skin cancer checks |
— | — | Private | — | 19 | 2009 | — |
| 50 |
DK North America
Advanced medical technology company focused on urology and radiology markets |
— | — | Unfunded | — | — | 2014 | — |
Developer of small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company leverages discovery and development platform Psybrary developing combination therapies with chemotherapeutic agents and immunotherapies for anxiety, depression, and addiction disorders.
Developer of immunotherapies for the treatment of cancer. The company is focused on developing novel personalized cancer vaccines and inhibitors of myeloid-derived suppressor cells(MDSCs). The company's lead candidate is IFx-2.0 personalized cancer vaccine involves a simple injection into a patient’s tumor of a small amount of pDNA that encodes for an immunogenic bacterial protein which gets expressed on the surfac
Developer of an AI-powered skin cancer detection device. The company offers DermaSensor device that uses a combination of cutting-edge optical spectroscopy and artificial intelligence to promptly analyze suspicious skin lesions. The device shines light bursts on a lesion, captures scattered light spectra, and uses proprietary AI algorithms to assess malignancy risk for melanoma, basal cell carcinoma, and squamous cel
Developer of a device for imaging diagnostics of cancer. It offers Time-Resolved Laser Induced Fluorescence Spectroscopy-based device to determine whether a brain lesion is benign or cancerous for resection of tumors.
Developer of molecular screening devices for the early detection of infectious diseases. The company develops a diversified portfolio of proprietary technologies and medical devices for the early identification of DNA and RNA virus-related pathologies. The product portfolio includes XytoTest and Anal test for cervical cancer, and HR-HPV DNA detection. Also, offers in-vitro diagnostic tests for the detection of HPV in
Developer of therapeutics for CNS-based disorders. The company has small molecule modulators which include MT-125 for different cancers, MT-110 for METH use disorders, and other substance use disorders.
Developer of therapeutic vaccines for the treatment of cancer. The company has developed Syncrovax platform by utilizing intratumoral sync technology (IST) to design cancer therapies. The product pipeline includes NSC-IST, BRC-IST, OVN-IST, PRC-IST for the treatment of lung, breast, ovarian, and breast cancers.
Developing innovative therapies targeting cancer and liver disease. This pharmaceutical company is dedicated to supplying new therapies for defeating deadly cancers and related diseases, improving the quality of life for patients with unmet needs. Founded as a spinoff, the company focuses on moving its pipeline of targeted radio-therapy, small molecule, and peptide-based drug compounds efficiently through the clinic
Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health. Its lead drug AG013 is a live biotherapeutic candidate formulated as oral rinsing solution to deliver the therapeutic molecule Trefoil Factor 1 (TFF1) to the mucosal tissues in the oral cavity.
Provider of cancer genetic diagnostic services. The company operates a network of cancer-focused testing labs, which is engaged in providing testing services to pathologists, oncologists, and other laboratories. The company provides services for cancer cytogenetics, hematologic and solid tumor FISH testing, 10-color flow cytometry, and nearly 100 molecular oncology tests comprising the most comprehensive combination
Developer of autologous natural killer (NK) cell therapies for cancer. These therapies are designed to be infused without lymphodepletion, broadening patient access and enabling convenient re-infusions. The approach aims for deeper, longer-lasting remissions by leveraging the intrinsic safety of NK cells and allowing them to cooperate with a fully intact host immune system. The company's pipeline focuses on minimal r
Developer of next-generation immunotherapy products. The lead product AlloStim is a bioengineered, non-genetically altered CD4+ Th1-like memory cell with anti-CD3/anti-CD28 coated microbead that has potent immunomodulatory properties and causes the down-regulation of checkpoint inhibitor molecules, such as PD-1/L1 and CTLA4. Chaperone Rich Cell Lysate are heat shock proteins purified from a lysed tumor or virally inf
HHS
Florida Institute
NIH
ARTEFIN
Abry
Adjuvant Capital
Alexandria
Ascent Biomedical Ventures
Aspen Capital
BioAdvance
Boma Investments
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-23.
_1541748952011.png){kind=logo}
_1584095366008.png){kind=logo}
